جست‌وجوی استاد و پژوهشگر

Christina Zielinskiمشاهده پروفایل

استاد

• T cell immunology
• Infection Immunology
• Regulation of human T cells
• +۷ مورد دیگر

Prof. Christina Zielinski is a W3-Professor and Chair of the Department of Infection Immunology at the Leibniz Institute for Natural Product Research and Infection Biology (Hans Knöll Institute) and University of Jena. She leads a dynamic research group focused on human T cell regulation in health and disease, with particular expertise in Th17 cells and their role in fungal infections like Candida albicans. Her research addresses fundamental questions about how protective and pathogenic T cell memory responses are shaped in human health and disease. Key areas of investigation include: Regulation of human T cells in physiological and pathological contexts Communication of human T cells with the tissue microenvironment Identification of pharmacological targets for T cell-based immunotherapies Mechanisms of tissue resident immunological memory Reciprocal interactions of T cells with fungi, microbiota, metabolites, and ions Prof. Zielinski's work has important translational implications for chronic infections, autoimmunity, and cancer. Her lab uses a translational and interdisciplinary approach combining analysis of healthy and pathological tissue samples with cutting-edge technologies, gene editing, and high-dimensional data analysis. Recent research has revealed how sodium chloride enhances T cell metabolic fitness in the tumor microenvironment and how Th17 cells engage gasdermin E pores to release IL-1α. Prof. Zielinski has received numerous prestigious awards including the medac research award 2023, Paul Langerhans Preis (2020), and the Celgene Award for Innovation in Inflammation and Immunology Research (2012). She was elected to the Board of the Germany Society for Immunology in 2023 and serves on the Editorial Board of the European Journal of Immunology. As a dedicated mentor, Prof. Zielinski is passionate about supporting junior scientists, particularly female scientists. She leads the Zielinski Lab, a young, ambitious, international, and interdisciplinary team of researchers. The lab is involved in several research projects including the ORGANise-T project funded by the European Research Council and the Collaborative Research Center 'FungiNet' focused on fungal infections.

• Liver Transcriptional Regulation
• Nuclear Receptor Signaling
• Cancer Promotion Mechanisms
• +۴ مورد دیگر

Joseph Locker, MD, PhD is Professor of Pathology at the University of Pittsburgh School of Medicine, with dual appointments in the Division of Experimental Pathology and Division of Molecular & Genomic Pathology. His research integrates basic transcriptional mechanisms with clinical pathology, focusing on liver disease processes. Dr. Locker's research interests center on liver transcriptional regulation , specifically examining how nuclear receptors like CAR and HNF4 control hepatocyte proliferation and metabolic functions. His work distinguishes cancer-promoting hyperplasia from natural regeneration processes, and investigates transcriptional deregulation in cirrhosis. Current projects utilize NextGen sequencing methodologies for genome-wide characterization of gene expression and chromatin remodeling. His publication record shows consistent productivity from the 1970s through 2025, with recent work spanning liver disease mechanisms, cancer biology, and molecular diagnostics. Research trends indicate increasing integration of genomic methodologies with traditional pathological analysis. As an active NIH-funded investigator, Dr. Locker maintains laboratory operations focused on translational research bridging molecular mechanisms with clinical applications in liver disease. His work provides fundamental insights into transcriptional control of liver regeneration and cancer promotion, with potential therapeutic implications for cirrhosis and hepatocellular carcinoma. Dr. Locker's clinical expertise includes molecular diagnostics, analysis of mutations and translocations, anatomic pathology, and immunohistochemistry. His dual MD/PhD training enables effective translation of basic research findings into clinical applications.

• Inflammation
• Pharmacology
• Immunology
• +۴ مورد دیگر

Professor Derek Gilroy serves as Professor of Experimental Inflammation and Pharmacology within the Division of Medicine at University College London, specializing in the active biological processes that resolve inflammation. His research challenges the traditional view of inflammation resolution as a passive process, instead demonstrating it as an active biological program with significant therapeutic implications for chronic inflammatory diseases. Professor Gilroy's educational background includes a Doctor of Philosophy from the William Harvey Research Institute at Queen Mary School of Medicine and Dentistry (1997), a Master of Science from Imperial College of Science, Technology and Medicine (1993), and a Diploma (1992). His academic trajectory reflects a deep commitment to understanding the molecular mechanisms underlying inflammatory processes. His research program centers on identifying endogenous pro-resolution pathways that could serve as novel therapeutic targets. Rather than simply suppressing inflammation, his work explores how to actively promote resolution mechanisms, representing a paradigm shift in treating chronic inflammatory conditions. This approach has significant implications for conditions ranging from rheumatoid arthritis to fibromyalgia, as evidenced by his diverse publication record. Analysis of Professor Gilroy's recent publications reveals a strong focus on cellular mechanisms of inflammation resolution, particularly involving macrophages, neutrophils, and specialized pro-resolving lipid mediators. His work spans from basic molecular mechanisms to clinical applications, with increasing attention to translational opportunities that could benefit patients suffering from chronic inflammatory conditions. Notably, his research has expanded to include investigations of SARS-CoV-2 immune responses and the long-term impacts of inflammation resolution on tissue integrity. Professor Gilroy actively contributes to academic training through his teaching responsibilities, including lecturing on the M.Sc course for Clinical and Experimental Medicine, examining Pharmacology Intercalated Research Projects, and participating in MPhil to PhD transfer examinations and PhD viva voce assessments. His mentorship extends to numerous research students and early-career scientists working in the field of inflammation research.

Christopher Rodellمشاهده پروفایل

استادیار

• Biomaterials
• Drug Delivery
• Supramolecular Chemistry
• +۳ مورد دیگر

Christopher Rodell, PhD, is an Assistant Professor in the School of Biomedical Engineering, Science and Health Systems at Drexel University. He leads the Tissue Instructive Materials Laboratory focusing on biomaterial design for therapeutic applications. His research integrates supramolecular chemistry, drug delivery, and immune engineering to develop novel therapies for cancer, cardiovascular disease, and organ injury. Education: Postdoctoral Scholar: Massachusetts General Hospital & Harvard Medical School (2016-2019) PhD in Bioengineering: University of Pennsylvania (2016) MS in Biomedical Engineering: Tulane University (2011) BS in Biomedical Engineering & Physics: Tulane University (2011) Research Focus: Dr. Rodell's work centers on creating injectable biomaterials (hydrogels, nanoparticles) for precision drug delivery and immune modulation. Key therapeutic areas include cancer immunotherapy (reprogramming tumor-associated macrophages), myocardial repair (hydrogel-based ventricular support), and renal disease management (targeted anti-inflammatory delivery). His research bridges fundamental material science with translational applications. Publications & Impact: With over 30 peer-reviewed articles and continuous output through 2025, his work demonstrates strong emphasis on nanoparticle-hydrogel hybrid systems for immunotherapy. Recent publications show growing focus on macrophage-targeted cancer therapies and advanced biomaterial characterization techniques. Key journals include Nature Biomedical Engineering , Advanced Materials , and Bioconjugate Chemistry . Awards & Honors: Materials Research Society Gold Award Solomon R. Pollack Award for Excellence in Graduate Research American Heart Association Predoctoral Fellowship Intellectual Property: Holds 3 patents including stabilized shear-thinning hydrogels (US Patent 9,827,321) and macrophage-targeted immunotherapeutics (patent pending).

Anna Fahlgrenمشاهده پروفایل

دانشیار

• Microbiology
• Immunology
• Infectious Diseases
• +۲ مورد دیگر

Anna Fahlgren is an Associate Professor at Umeå University, affiliated with the Faculty of Medicine and the Department of Molecular Biology. She serves as the Education Manager at the Faculty Office of Medicine, overseeing education, research, and communication initiatives. Her administrative role is based in the Administration Building, while her research ties to molecular biology are centered at the hospital area campus. Her research focuses on microbial pathogenesis , host immune responses , and bacterial infection mechanisms . Key areas include: virulence strategies of pathogens like Yersinia pseudotuberculosis and Campylobacter jejuni , immune evasion tactics, outer membrane vesicle functions, and host-pathogen interactions in gastrointestinal and systemic infections. Recent publications (2012–2024) demonstrate a consistent focus on: Bacterial virulence regulation (e.g., plasmid dynamics, secretion systems) Host immune modulation (e.g., neutrophil interactions, mast cell activation) Co-infections and pathological synergies (e.g., malaria-borrelia models) Molecular mechanisms of persistence and adaptation in infections She collaborates with the Maria Fällman Lab , contributing to research on bacterial pathogenesis. No awards, students, or grant details are mentioned in the provided text.

Irene Bertoliniمشاهده پروفایل

پژوهشگر ارشد

• Cancer Biology
• Tumor Microenvironment
• Extracellular Vesicles
• +۶ مورد دیگر

Irene Bertolini, Ph.D., is a Caspar Wistar Fellow in the Molecular and Cellular Oncogenesis Program at the Ellen and Ronald Caplan Cancer Center of The Wistar Institute in Philadelphia. She leads an independent research laboratory focused on investigating the role of extracellular vesicles in regulating cell-to-cell communication within the tumor microenvironment. Dr. Bertolini received her Ph.D. in Molecular and Translational Medicine from the University of Milan (Italy) in 2018. She then moved to Philadelphia to join Dr. Dario Altieri's laboratory at The Wistar Institute, where she was promoted to a staff scientist position before accepting her current role as a Caspar Wistar Fellow in 2024. Her research program centers on understanding how extracellular vesicles shape the tumor microenvironment and metastatic niche in glioblastoma and breast cancer. Specifically, her laboratory investigates (i) the role of microglia-derived extracellular vesicles in shaping the glioma tumor microenvironment and (ii) the contribution of extracellular vesicles released in hypoxic conditions by breast cancer cells to preparing the pre-metastatic niche. Her work combines sophisticated in vitro and in vivo approaches to unravel complex signaling mechanisms involved in tumor progression and immune evasion. Her publication record demonstrates expertise across cancer biology, with particular emphasis on hypoxia-induced changes in tumor behavior, mitochondrial dynamics, and the role of extracellular vesicles in cancer progression. Her research bridges fundamental molecular mechanisms with potential therapeutic applications. Current laboratory members include Postdoctoral Fellow Miguel Quiralte Pulido, Ph.D., and Research Assistant Isabela Albuja Ron Committed to mentorship through the MentorFirst initiative Active researcher with publications spanning 2020-2025 in high-impact journals Dr. Bertolini's work represents an important contribution to understanding the complex communication networks within tumors that drive cancer progression and metastasis.

Andrew Kossenkovمشاهده پروفایل

استادیار

• Bioinformatics
• Computational Biology
• Cancer Genomics
• +۷ مورد دیگر

Andrew Kossenkov, Ph.D. serves as an Assistant Professor at The Wistar Institute, specifically within the Vaccine & Immunotherapy Center and the Genome Regulation and Cell Signaling Program of the Ellen and Ronald Caplan Cancer Center. His career trajectory began with bachelor's and master's degrees in computer science and bioinformatics from Moscow Engineering Physics Institute in Russia, followed by a Ph.D. in biomedical science from Drexel University in Philadelphia. He joined The Wistar Institute in 2007 as a postdoctoral fellow in the Showe lab and subsequently became managing director of the Bioinformatics Facility before his 2019 appointment as Assistant Professor. Dr. Kossenkov's research focuses on applying computational approaches to analyze various kinds of biomedical high-throughput data, with particular expertise in interpreting results and visualizing complex datasets. His laboratory collaborates extensively with other Wistar labs on research projects spanning cancer, infectious diseases, and fundamental biological questions including regeneration, stem cell biology, mitochondrial proteins, transcriptional regulation, synapse biology, blood development, and global epigenetic gene silencing. The Kossenkov Laboratory relies heavily on bioinformatics analysis of drug screen results, next-generation sequencing data, and proteomics. His publication record reveals a strong focus on cancer immunology, particularly ovarian cancer, melanoma, and breast cancer, with significant contributions to understanding how metabolic reprogramming, mitochondrial dynamics, and immune microenvironment interactions influence tumor progression and treatment response. His work often bridges computational biology with experimental validation through extensive collaborations across multiple institutions including Fox Chase Cancer Center, The Children's Hospital of Philadelphia, the University of Pennsylvania, Drexel University, New York University, Weill Cornell, and Harvard. Through his leadership of the Bioinformatics Facility, Dr. Kossenkov provides critical expertise for high-throughput data support, analysis, and annotation, developing database-oriented gene annotation pipelines and algorithms to visualize highly specific and intricate results. His laboratory offers flexible and customizable support for a wide range of experiments across multiple research domains, making significant contributions to both computational methodology development and biological discovery.

• Hematology
• Oncology
• Stem Cell Biology
• +۴ مورد دیگر

Andrew DeVilbiss, Ph.D., serves as an Instructor (academic rank equivalent to Lecturer) in the Department of Internal Medicine at UT Southwestern Medical Center, where he is a member of the Division of Hematology and Oncology. He joined the faculty in 2024 following a postdoctoral fellowship at UT Southwestern's Children's Research Institute. Education: Dual bachelor's degrees in Biochemistry and Cellular and Molecular Biology from the University of Wisconsin Ph.D. in Philosophy from the University of Wisconsin Postdoctoral fellowship at UT Southwestern Medical Center's Children's Research Institute Dr. DeVilbiss' research program centers on the molecular and metabolic regulation of hematopoiesis, with particular emphasis on hematopoietic stem cell biology, erythroid maturation, and leukemogenesis. His work integrates transcriptional regulation, epigenetics, and metabolism to dissect how genetic networks control blood cell development and disease. Key investigations include the role of GATA factors, chromatin modifiers, and metabolic pathways such as ascorbate metabolism and redox regulation in stem cell function and blood disorders. Analysis of his publication record (2013-2025) reveals an evolving research trajectory from foundational studies on transcriptional mechanisms in hematopoiesis toward contemporary investigations of metabolic regulation in stem cells. Recent work (2021-2025) demonstrates significant focus on ascorbate deficiency, redox sensors (KEAP1), and autophagy in stem cell quiescence, self-renewal, and aging, with implications for neutropenia, T cell dysfunction, and acute myeloid leukemia. His publications span high-impact journals including Blood, Science Immunology, and Cell Stem Cell. No scientific awards are listed in the provided information. No information regarding student advising or research grants is available in the provided text. There is no mention of specific laboratory groups or research teams led by Dr. DeVilbiss in the provided material.

• Immunology
• Myelopoiesis
• Trained Immunity
• +۲ مورد دیگر

Lydia Kalafati is an Assistant Professor (W1 Junior Professorship) in the Faculty of Medicine at TUD Dresden University of Technology and Junior Group Leader of the Dresden Concept Research Group, a joint initiative with Helmholtz-Zentrum Dresden-Rossendorf and Leibniz-Institut für Polymerforschung. Her research group, 'Inflammation and Myelopoiesis,' studies how inflammatory cues regulate blood cell production and trained immunity in cancer and autoimmune diseases. Her educational background includes: PhD in Immunology from TUD Dresden University of Technology (2022, summa cum laude ) MSc in Molecular Basis of Human Diseases from University of Crete (2017, Excellent distinction) BSc in Biomolecular Sciences and Biotechnology from University of Crete (2011–2015) Research interests center on: Immunological mechanisms : Trained immunity, neutrophil biology, and myeloid cell dynamics Disease applications : Cancer immunotherapy, inflammatory comorbidities, and autoimmune pathogenesis Technical approaches : Single-cell multi-omics, epigenetic mapping, and preclinical disease modeling Her publications emphasize translational immunology, with recent work exploring granulopoiesis reprogramming for anti-tumor responses and mitochondrial dysregulation in autoimmunity. Awards include PhD honors for innovative cancer immunotherapy research. Current projects leverage cross-disciplinary collaborations to develop biomaterial-enhanced cellular therapies, supported by advanced imaging and sequencing infrastructure. As an emerging group leader, she is establishing her team with a focus on myeloid immunology innovation.

• Atherosclerosis
• Thrombosis
• CD36 Signaling
• +۵ مورد دیگر

Roy L. Silverstein, MD, is a Professor in the Department of Medicine at the Medical College of Wisconsin (MCW). He holds key affiliations with MCW's research centers, including the Cancer Center, Cardiovascular Research Center, Center for Disease Prevention Research, and Mellowes Center for Genomic Sciences and Precision Medicine, highlighting his interdisciplinary focus. His research explores mechanisms of atherosclerosis, thrombosis, and inflammation, with emphasis on: CD36 scavenger receptor signaling in macrophages and platelets Oxidative stress and redox regulation in vascular disease Lipid metabolism and metabolic inflammation Thrombospondin-mediated angiogenesis modulation Analysis of recent publications (2022-2025) reveals dominant themes: CD36's role in platelet hyperreactivity and thrombosis in metabolic disorders Ion transport (Na/K-ATPase) intersections with inflammation Macrophage metabolic reprogramming in atherosclerosis Translational studies informing clinical guidelines for thrombotic disorders While no awards are listed in the source text, his extensive publication record in high-impact journals underscores significant scholarly contributions. He mentors through research collaborations but no specific advisees are named.

• Redox Signaling
• Epigenetics
• Trained Immunity
• +۵ مورد دیگر

Christian Lindermayr is a Professor at Helmholtz Munich , affiliated with the Environmental Health Center and the Institute of Lung Health and Immunity . He leads the research group 'Trained Immunity', focusing on redox signaling, epigenetic mechanisms, and their role in innate immune memory in both plants and humans. His work bridges plant biochemistry and human immunology to develop immunotherapies for trained immunity modulation. PhD in Plant Physiology and Biochemistry from Ludwig-Maximilians-University Munich (2002) Habilitation in Plant Biochemistry at Technical University of Munich (2016) Group Leader at Helmholtz Munich since 2008 Appointed Adjunct Professor by TUM (2023) His research interests encompass redox processes, epigenetic regulation, trained immunity, and climate change effects on immune responses. The lab investigates how reactive oxygen and nitrogen species (ROS/NO) drive metabolic and epigenetic reprogramming during immune training, with applications to human lung health and agricultural sustainability. Publication trends highlight interdisciplinary studies on redox signaling, epigenetic mechanisms, and trained immunity across plant and human systems. Key topics include histone modifications, stress gene regulation, climate-resilient crops, and immune memory in the lung. Professional roles include: President, Plant Oxygen Group (2024–) Full Member, Sigma Xi Honor Society (2022–) Treasurer, Verband Biologie, Biowissenschaften & Biomedizin in Deutschland (2020–) He mentors PhD students Nancy Dhyani and Mansi Kumari, and leads cross-institutional collaborations at the intersection of plant science and human immunology.

• Apoptosis
• Cell Fate Regulation
• Immunotoxicology
• +۷ مورد دیگر

Andrea I. Doseff is a Professor at Michigan State University with joint appointments in the Department of Physiology and Department of Pharmacology and Toxicology . Her research explores fundamental mechanisms of apoptosis and cell fate regulation , particularly in immune cells and cancer contexts. Education: B.Sc. in Biology from University of Buenos Aires Ph.D. from State University of New York at Cold Spring Harbor Laboratory Her work integrates multi-omics approaches to define regulatory networks controlling cell death, while pioneering research on phytochemicals that reprogram immune function and reverse disease states. She leads efforts to translate these findings into functional food designs for cancer prevention and chronic disease management. Key publication themes include: RNA splicing in myeloid cells Flavonoid molecular targets Inflammation-cancer axis Systems biology of apoptosis Contact: doseffan@msu.edu

• Immunology
• Virology
• Vaccine Development
• +۵ مورد دیگر

Akiko Iwasaki is Sterling Professor of Immunobiology at Yale School of Medicine, with secondary appointments in Dermatology and Epidemiology of Microbial Diseases. She serves as Director of Yale's Center for Infection and Immunity and has been an HHMI Investigator since 2014. Her affiliations include joint roles with Yale Cancer Center, Center for RNA Science, and Women's Health Research at Yale. Her research focuses on: Mucosal immune defense mechanisms against viruses Long COVID pathophysiology and neuroimmune interactions Development of nasal vaccines to block viral transmission Virus-triggered autoimmunity and cancer pathogenesis Recent publications emphasize SARS-CoV-2 immunology, with trends showing strong focus on: Characterization of post-viral syndromes (Long COVID, ME/CFS) Mucosal vaccine efficacy and IgA response modulation Viral reservoir identification and therapeutic targeting Neuroimmune mechanisms in chronic disease Major scientific honors include: Keio Medical Science Prize (2025) TIME 100 Most Influential People (2024) National Academy of Sciences membership (2018) Else Kröner Fresenius Prize (2023) AAI Presidency (2023) She directs the Iwasaki Lab and Center for Infection and Immunity, coordinating multicenter studies like the Yale-Mount Sinai Long COVID initiative. As principal investigator of NIH-funded projects, she mentors graduate students and oversees translational research bridging virology and clinical immunology.

• Cancer Genetics
• Cancer Epigenetics
• Immunobiology
• +۵ مورد دیگر

Vish Muthusamy is a Research Scientist at Yale School of Medicine with appointments in the Department of Medical Oncology and Hematology and the Developmental Therapeutics Program. He serves as the Director of the Center for Precision Cancer Modeling at Yale Cancer Center, where he focuses on advancing candidate therapeutic agents toward clinical application. Dr. Muthusamy is a cancer biologist with expertise spanning multiple disciplines: Cancer genetics and epigenetics Immunobiology and immunotherapy Pharmacological development of anti-cancer drugs Preclinical modeling and testing His research program focuses on understanding genetic alterations that drive cancer formation and progression, developing in vivo tumor models, and translating these findings into therapeutic approaches. Dr. Muthusamy frequently collaborates with medicinal chemists and has worked with both large and small pharmaceutical companies to develop therapeutic agents targeting cancer, infectious pathogens, and immune disorders. As Director of the Center for Precision Cancer Modeling, he plays a key role in Yale's translational research ecosystem, helping investigators bridge the gap between laboratory discoveries and clinical applications. Dr. Muthusamy's publication record demonstrates a strong trajectory from basic cancer biology to translational drug development. His recent work (2023-2025) focuses on overcoming checkpoint inhibitor resistance through novel immunotherapies, including IL-12 mRNA therapy and CD40 agonists. Earlier work (2016-2022) includes research on targeted therapies for specific cancer types like FGFR3-driven bladder cancer, metabolic isozyme targets in cancer, and innovative approaches to protein degradation and immune recruitment. Dr. Muthusamy maintains active collaborations across Yale and with external partners. His frequent co-authors include Katerina Politi, Marcus Bosenberg, Akiko Iwasaki, Anna Marie Pyle, and Daniel P. Petrylak, indicating strong connections across cancer biology, immunology, and clinical oncology disciplines. As Director of the Center for Precision Cancer Modeling, Dr. Muthusamy leads a research team focused on preclinical development of cancer therapeutics. The center provides expertise in developing and validating tumor models that better predict clinical response, helping Yale researchers advance their discoveries toward clinical trials and eventual patient care.

Saskia Trumpمشاهده پروفایل

پژوهشگر

• Epigenetics
• Molecular Epidemiology
• Environmental Health
• +۳ مورد دیگر

Saskia Trump is a Researcher in Molecular Epidemiology at Charité Universitätsmedizin Berlin and the Berlin Institute of Health, affiliated with Irina Lehmann's Lab. Her work bridges epigenetics, environmental health, and molecular biology, focusing on how exposures like air pollution, toxins, and viral infections drive diseases such as asthma, COVID-19, hypertension, and cancer through mechanisms like DNA methylation and immune dysregulation. Her research interests include: Epigenetic Regulation: DNA methylation changes in response to environmental stressors (e.g., air pollution, maternal smoking) and their role in asthma, allergies, and transgenerational health effects. Viral Pathogenesis: Host-pathogen interactions in COVID-19, including epigenetic memory, immune responses, and comorbidities like hypertension. Cancer Metabolism: Aryl hydrocarbon receptor (AHR) signaling, tryptophan catabolism, and metabolic reprogramming in glioblastoma and other cancers. Trump's recent articles (2022–2025) emphasize SARS-CoV-2 epigenetics, pediatric health, and environmental toxicology. Trends show a strong focus on single-cell genomics, DNA methylation sequencing, and translational applications for respiratory and metabolic diseases. She collaborates extensively across disciplines, contributing to studies on cystic fibrosis, glioblastoma, and childhood asthma. Current lab projects explore: Long-term epigenetic effects of COVID-19 in airway cells. Impact of moderate air pollution on respiratory epigenomes. Metabolic-immune crosstalk in cancer progression.